Market Overview

Deutsche Bank Sees Achillion, Arrowhead As Potential Takeover Targets

Share:
Related ACHN
What Does The Johnson & Johnson/Achillion Deal Mean For HCV Competitors?
Morning Market Losers
Stake Bets: Point72 on Achillion (ACHN), Stonepine Capital on Aegerion (AEGR), CPPIB on Enstar (ESGR) (Small Cap Network)

Achillion Pharmaceuticals (NASDAQ: ACHN) and Arrowhead Research (NASDAQ: ARWR) were up sharply Tuesday after an analyst said the pair of drug development companies could become takeover targets.

"If you want to compete with Gilead, you have to buy Achillion," Deutsche Bank's Robyn Karnauskas said on CNBC. "We think that's one take-out target."

Karnauskas noted Achillion's pipeline has promising treatments for hepatitis.

A similar appraisal of Achillion came Monday from UBS's Andrew Peters, who highlighted "a scarcity of de-risked assets."

Speculation about the acquisition of development-stage drug companies has been rife after InterMune (NASDAQ: ITMN) agreed to an $8.3 billion buyout by Roche on Sunday.

Kanauskas appearing on CNBC's "Fast Money" program Monday evening, also said Arrowhead Research "may be attractive" if it releases positive data for its hepatitis drug later this autumn,

Achillion traded recently at $11.65, up eight percent; Arrowhead traded at $15.13, up 12.6 percent.

Latest Ratings for ACHN

DateFirmActionFromTo
May 2015UBSDowngradesBuyNeutral
May 2015William BlairUpgradesMarket PerformOutperform
May 2015JMP SecuritiesDowngradesMarket OutperformMarket Perform

View More Analyst Ratings for ACHN
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color CNBC News Dividends Intraday Update Analyst Ratings Media

 

Related Articles (ACHN + ARWR)

Around the Web, We're Loving...